👶Pregnancy
Studies of atypical antipsychotics as a group have not shown a large increase in major birth defects, but data for asenapine specifically are limited. Use during the third trimester is associated with risk of extrapyramidal and/or withdrawal symptoms in the newborn (e.g., agitation, abnormal muscle tone, feeding difficulties, respiratory distress). Stopping effective antipsychotic treatment can markedly increase the risk of relapse, which itself can harm pregnancy. Use the lowest effective dose, avoid polypharmacy when possible, and manage as part of a shared decision-making process with psychiatry and obstetrics.🤱Breastfeeding
It is not clearly known whether asenapine is present in human breast milk, but similar medications can be excreted and may cause sedation, poor feeding, or abnormal movements in infants. If used while breastfeeding, use the lowest effective dose, avoid additional sedating medications, and monitor the infant for sleepiness, feeding problems, or unusual movements. Discuss risks and benefits with your prescriber.👧Children & Adolescents (Under 18)
Sublingual asenapine is approved for acute manic or mixed episodes in bipolar I disorder for ages 10–17. Children and adolescents may be more sensitive to weight gain, metabolic changes, and movement symptoms. Growth, weight, metabolic parameters, and movement should be monitored regularly.👴Older Adults (65+)
Older adults are at higher risk of orthostatic hypotension, sedation, falls, stroke, and mortality when taking antipsychotics—especially those with dementia-related psychosis. Use only when clearly indicated, at the lowest effective dose, and reassess frequently.🔬Liver Impairment
Severe hepatic impairment (Child-Pugh C) leads to ~7-fold increase in exposure and is a contraindication. Mild to moderate impairment requires careful dosing and monitoring.💧Kidney Impairment
No formal adjustment is typically required, but comorbidities and polypharmacy should be considered.